165 related articles for article (PubMed ID: 37946261)
21. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
22. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
23. HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.
Beltjens F; Bertaut A; Pigeonnat S; Loustalot C; Desmoulins I; Charon-Barra C; Coudert B; Fumoleau P; Arveux P; Arnould L
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26503126
[TBL] [Abstract][Full Text] [Related]
24. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
25. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
26. Quality assessment of HER2 testing by monitoring of positivity rates.
Choritz H; Büsche G; Kreipe H;
Virchows Arch; 2011 Sep; 459(3):283-9. PubMed ID: 21809092
[TBL] [Abstract][Full Text] [Related]
27. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization.
Vogel UF
Diagn Pathol; 2010 Jul; 5():50. PubMed ID: 20670419
[TBL] [Abstract][Full Text] [Related]
28. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
29. Quality of pathology reporting is crucial for cancer care and registration: a baseline assessment for breast cancers diagnosed in Belgium in 2008.
De Schutter H; Van Damme N; Colpaert C; Galant C; Lambein K; Cornelis A; Neven P; Van Eycken E
Breast; 2015 Apr; 24(2):143-52. PubMed ID: 25572136
[TBL] [Abstract][Full Text] [Related]
30. Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries.
Crocetti E; Caldarella A; Ferretti S; Ardanaz E; Arveux P; Bara S; Barrios E; Bento MJ; Bordoni A; Buzzoni C; Candela G; Colombani F; Delafosse P; Federico M; Francart J; Giacomin A; Grosclaude P; Guizard AV; Izarzugaza I; Konzelmann I; La Rosa F; Lapotre B; Leone N; Ligier K; Mangone L; Marcos-Gragera R; Martinez R; Michelena MJ; Michiara M; Miranda A; Molinié F; Mugarza-Gomez C; Paci E; Piffer S; Puig-Vives M; Sacchettini C; Sánchez MJ; Traina A; Tretarre B; Tumino R; Van Vaerenbergh E; Velten M; Woronoff AS
Breast; 2013 Aug; 22(4):476-81. PubMed ID: 23669022
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
Musolino A; Falcini F; Sikokis A; Boggiani D; Rimanti A; Pellegrino B; Silini EM; Campanini N; Barbieri E; Zamagni C; Degli Esposti R; Cortesi L; Bisagni G; Cavanna L; Frassoldati A; Sgargi P; Michiara M
Eur J Cancer; 2018 Jan; 88():10-20. PubMed ID: 29175735
[TBL] [Abstract][Full Text] [Related]
32. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
33. The assessment of HER2 status in breast cancer: the past, the present, and the future.
Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
[TBL] [Abstract][Full Text] [Related]
34. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
Kaufman PA; Bloom KJ; Burris H; Gralow JR; Mayer M; Pegram M; Rugo HS; Swain SM; Yardley DA; Chau M; Lalla D; Yoo B; Brammer MG; Vogel CL
Cancer; 2014 Sep; 120(17):2657-64. PubMed ID: 24930388
[TBL] [Abstract][Full Text] [Related]
35. Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study.
Musolino A; Michiara M; Conti GM; Boggiani D; Zatelli M; Palleschi D; Bella MA; Sgargi P; Di Blasio B; Ardizzoni A
J Clin Oncol; 2012 Jul; 30(19):2362-8. PubMed ID: 22585698
[TBL] [Abstract][Full Text] [Related]
36. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
[TBL] [Abstract][Full Text] [Related]
37. HER2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes.
Lee HJ; Lee JE; Jeong WG; Ki SY; Park MH; Lee JS; Nah YK; Lim HS
AJR Am J Roentgenol; 2022 Feb; 218(2):258-269. PubMed ID: 34431365
[No Abstract] [Full Text] [Related]
38. Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
Huang Y; Burns DJ; Rich BE; MacNeil IA; Dandapat A; Soltani SM; Myhre S; Sullivan BF; Lange CA; Furcht LT; Laing LG
BMC Cancer; 2017 Mar; 17(1):199. PubMed ID: 28302091
[TBL] [Abstract][Full Text] [Related]
39. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
El Hadi H; Abdellaoui-Maane I; Kottwitz D; El Amrani M; Bouchoutrouch N; Qmichou Z; Karkouri M; ElAttar H; Errihani H; Fernandez PL; Bakri Y; Sefrioui H; Moumen A
Gene; 2017 Mar; 605():114-122. PubMed ID: 28039034
[TBL] [Abstract][Full Text] [Related]
40. Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Viale G; Paterson J; Bloch M; Csathy G; Allen D; Dell'Orto P; Kjærsgaard G; Levy YY; Jørgensen JT
Pathol Res Pract; 2016 Aug; 212(8):735-42. PubMed ID: 27461826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
